Heron Therapeutics signs US multi-product development, license deal with Long Grove Pharmaceuticals
Bitget2026/09/29 21:00- Heron Therapeutics entered a multi-product development and license agreement with Long Grove Pharmaceuticals, with Capstone providing exclusivity covenants.
- Deal grants an exclusive, sublicensable US license to import, distribute, sell, and market certain products covered by licensed patents.
- Heron also received a non-exclusive worldwide manufacturing license for products sold in the US territory.
- Long Grove is eligible for regulatory milestones, sales-based milestones, and royalties; Heron will be reimbursed for certain expenses.
- Agreement runs 10 years from first commercial sale, with automatic two-year renewals.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Financial Report Soared 322% but Shares Fell Nearly 4%: Technical Death Cross Suppresses APLD (APLD.US)
App’s Q1 revenue reached $300 millions, surpassing expectations. However, due to weakness in tech stocks and a technical death cross, the stock price fell by 3.78%. Analysts maintain a buy rating and are closely watching whether the key support level at $19.5 can hold.
Getty bankruptcy privatization: AI impact collapses a 5 billion empire
Getty Images has filed for bankruptcy due to the impact of AI and a debt crisis, with its stock price plummeting by 99.95%. The family and Koch Equity have injected $533 millions for privatization, aiming to transition toward AI training authorization.
Storage stocks suffer growing pains from a narrative shift! Roundhill suggests a "barbell strategy": large-cap growth plus "halo stocks"
Drew Pettit, Chief Investment Strategist at Roundhill Investments, stated that the market does not favor stocks with a transitional narrative, and currently, storage stocks are in such an awkward position.
The largest single-week net purchase in fifteen years! Citadel analyst: Retail investors are buying AI stocks again
Retail investors are bottom-fishing AI stocks, with a net purchase of $9.1 billion in one week, marking a 15-year record! According to Citadel Securities data, funds are highly concentrated in semiconductors and AI infrastructure. However, this is not a broad-based buying frenzy, but rather a directional overweight, with buying skewed to the 90th percentile of the past year.
Crypto prices
More
